Aberdeen Group’s Novavax NVAX Stock Holding History

Aberdeen Group’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-37,188	Closed	-$234K	–	972
2025 Q2	$234K	Sell	37,188 -26,612	-42%	-$176K	﹤0.01%	939
2025 Q1	$409K	Hold	63,800	–	–	﹤0.01%	885
2024 Q4	$513K	Hold	63,800	–	–	﹤0.01%	870
2024 Q3	$806K	Hold	63,800	–	–	﹤0.01%	822
2024 Q2	$808K	Hold	63,800	–	–	﹤0.01%	832
2024 Q1	$305K	Hold	63,800	–	–	﹤0.01%	901
2023 Q4	$306K	Buy	+63,800	New	+$391K	﹤0.01%	910
2022 Q2	–	Sell	-7,000	Closed	-$519K	–	975
2022 Q1	$519K	Buy	7,000 +2,272	+48%	+$203K	﹤0.01%	895
2021 Q4	$676K	Buy	4,728 +41	+0.9%	+$7.04K	﹤0.01%	932
2021 Q3	$972K	Buy	4,687 +2,961	+172%	+$653K	﹤0.01%	891
2021 Q2	$366K	Buy	+1,726	New	+$316K	﹤0.01%	967

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aberdeen Group's NVAX Position: Q3 2025 in Review

Aberdeen Group sold out of Novavax (NVAX) in Q3 2025, closing a stake of 37,188 shares — an estimated $234K sold.

Aberdeen Group first reported a position in NVAX in Q2 2021 and held it in 11 quarters. The position peaked at $972K in Q3 2021. 249 funds tracked by Wall St. Rank hold NVAX as of Q3 2025.

Aberdeen Group reported no remaining Novavax position as of Q3 2025 after selling out during the quarter.
Aberdeen Group sold 37,188 Novavax shares in Q3 2025, an estimated $234K.
Aberdeen Group first reported a position in Novavax in Q2 2021 and held it in 11 quarters.
Aberdeen Group's Novavax position peaked at $972K in Q3 2021.
249 funds tracked by Wall St. Rank held Novavax as of Q3 2025.

Based on Aberdeen Group's 13F filing for Q3 2025, filed 7 Nov 2025.